Phenotypes Associated with This Genotype

Genotype
MGI:5296806

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-Esr1)#Paf/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

abnormal mammary gland morphology ( J:96383 )

♀ • ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities

♀ • exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ

♀ • neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants

♀ • mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development

abnormal mammary gland epithelium morphology ( J:96383 )

♀ • rates of mammary epithelial cell proliferation are increased compared to controls

abnormal mammary gland duct morphology ( J:96383 )

♀ • at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching

abnormal branching of the mammary ductal tree ( J:96383 )

♀ • at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts

mammary gland duct hyperplasia ( J:96383 )

♀ • 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia

abnormal mammary gland lobule morphology ( J:96383 )

♀ • 52% of mutants at 4 months of age show lobular hyperplasia

mammary gland alveolar hyperplasia ( J:96383 )

♀ • 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias

increased mammary gland ductal carcinoma incidence ( J:96383 )

• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

neoplasm

increased mammary gland ductal carcinoma incidence ( J:96383 )

• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

integument

abnormal mammary gland morphology ( J:96383 )

♀ • exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ

♀ • neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants

♀ • ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities

♀ • mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development

abnormal mammary gland epithelium morphology ( J:96383 )

♀ • rates of mammary epithelial cell proliferation are increased compared to controls

abnormal mammary gland duct morphology ( J:96383 )

♀ • at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching

abnormal branching of the mammary ductal tree ( J:96383 )

♀ • at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts

mammary gland duct hyperplasia ( J:96383 )

♀ • 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia

abnormal mammary gland lobule morphology ( J:96383 )

♀ • 52% of mutants at 4 months of age show lobular hyperplasia

mammary gland alveolar hyperplasia ( J:96383 )

♀ • 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias

increased mammary gland ductal carcinoma incidence ( J:96383 )

• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:96383